Export

ATC codes: L01XA02
EMLc
Indication
Retinoblastoma ICD11 code: 2D52.2
INN
Carboplatin
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > unspecified: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL
EML status history
First added in 2009 (TRS 958)
Changed in 2015 (TRS 994)
Sex
All
Age
Also recommended for children
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for retinoblastoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of the treatment protocols for retinoblastoma is attached.